The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
Open accessAbstract
As distinct cancer biomarkers have been discovered in recent years, a need to reclassify tumors by more than their histology has been proposed, and therapies are now tailored to treat cancers based on specific molecular aberrations and immunologic markers. In fact, multiple histology‐agnostic therapies are currently adopted in clinical practice for treating patients regardless of their tumor site of origin. In parallel with this new model for drug development, in the past few years, several novel antibody–drug conjugates (ADCs) have been approved to treat solid tumors, benefiting from engineering improvements in the conjugation process and the introduction of novel linkers and payloads. With the recognition that numerous surface targets are expressed across various cancer histologies, alongside the remarkable activity of modern ADCs, this drug class has been increasingly evaluated as suitable for a histology‐agnostic expansion of indication. For illustration, the anti‐HER2 ADC trastuzumab deruxtecan has demonstrated compelling activity in HER2‐overexpressing breast, gastric, colorectal, and lung cancer. Examples of additional novel and potentially histology‐agnostic ADC targets include trophoblast cell‐surface antigen 2 (Trop‐2) and nectin‐4, among others. In the current review article, the authors summarize the current approvals of ADCs by the US Food and Drug Administration focusing on solid tumors and discuss the challenges and opportunities posed by the multihistological expansion of ADCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.66 · Cited by 3,079
Marabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., De Jesus-Acosta, A., Delord, J.-P., Geva, R., Gottfried, M., Penel, N., Hansen, A. R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02105 · Cited by 3,048
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
von Minckwitz, G., Huang, C.-S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814017 · Cited by 2,625
Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Self-citationTrastuzumab deruxtecan in previously treated HER2-positive breast cancer
Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914510 · Cited by 2,006
Self-citationDoebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., Cho, B. C., Tosi, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30691-6 · Cited by 1,790
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2014) · Archives of Pathology and Laboratory Medicine · doi:10.5858/arpa.2013-0953-sa · Cited by 1,762
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Bardia, A., Hurvitz, S. A., Tolaney, S. M., Loirat, D., Punie, K., Oliveira, M., Brufsky, A., Sardesai, S. D., Kalinsky, K., Zelnak, A. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028485 · Cited by 1,711
Self-citationCurrent treatment and recent progress in gastric cancer
Joshi, S. S., & Badgwell, B. D. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21657 · Cited by 1,677
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676
Wolff, A. C., Hammond, M. E. H., Allison, K. H., Harvey, B. E., Mangu, P. B., Bartlett, J. M. S., Bilous, M., Ellis, I. O., Fitzgibbons, P., Hanna, W., et al. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0902-sa · Cited by 1,474
Paul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369
Self-citationTrastuzumab deruxtecan in previously treated HER2-positive gastric cancer
Shitara, K., Bang, Y.-J., Iwasa, S., Sugimoto, N., Ryu, M.-H., Sakai, D., Chung, H.-C., Kawakami, H., Yabusaki, H., Lee, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004413 · Cited by 1,333
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
Powles, T., Rosenberg, J. E., Sonpavde, G. P., Loriot, Y., Durán, I., Lee, J.-L., Matsubara, N., Vulsteke, C., Castellano, D., Wu, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035807 · Cited by 1,229
Unlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,150
Self-citationHER2-targeted therapies — a role beyond breast cancer
Oh, D.-Y., & Bang, Y.-J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0268-3 · Cited by 1,081
Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., van Tilburg, C. M., Nagasubramanian, R., Berlin, J. D., Federman, N., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30856-3 · Cited by 1,028
Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer
Li, B. T., Smit, E. F., Goto, Y., Nakagawa, K., Udagawa, H., Mazières, J., Nagasaka, M., Bazhenova, L., Saltos, A. N., Felip, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2112431 · Cited by 1,021
Dose Escalation Methods in Phase I Cancer Clinical Trials
Le Tourneau, C., Lee, J. J., & Siu, L. L. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp079 · Cited by 867
HER2-Low Breast Cancer: Pathological and Clinical Landscape
Tarantino, P., Hamilton, E., Tolaney, S. M., Cortes, J., Morganti, S., Ferraro, E., Marra, A., Viale, G., Trapani, D., Cardoso, F., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02488 · Cited by 791
Self-citationModi, S., Park, H., Murthy, R. K., Iwata, H., Tamura, K., Tsurutani, J., Moreno-Aspitia, A., Doi, T., Sagara, Y., Redfern, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02318 · Cited by 787
Self-citationBurris, H. A., Rugo, H. S., Vukelja, S. J., Vogel, C. L., Borson, R. A., Limentani, S., Tan-Chiu, E., Krop, I. E., Michaelson, R. A., Girish, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.5865 · Cited by 764
Nishino, M., Giobbie-Hurder, A., Hatabu, H., Ramaiya, N. H., & Hodi, F. S. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2453 · Cited by 758
Challita-Eid, P. M., Satpayev, D., Yang, P., An, Z., Morrison, K., Shostak, Y., Raitano, A., Nadell, R., Liu, W., Lortie, D. R., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1313 · Cited by 724
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
Van Cutsem, E., Bang, Y.-J., Feng-yi, F., Xu, J. M., Lee, K.-W., Jiao, S.-C., Chong, J. L., López-Sanchez, R. I., Price, T., Gladkov, O., et al. (2015) · Gastric Cancer · doi:10.1007/s10120-014-0402-y · Cited by 608
Krop, I. E., Beeram, M., Modi, S., Jones, S. F., Holden, S. N., Yu, W., Girish, S., Tibbitts, J., Yi, J.-H., Sliwkowski, M. X., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2071 · Cited by 595
Self-citationLi, B. T., Shen, R., Buonocore, D., Olah, Z. T., Ni, A., Ginsberg, M. S., Ulaner, G. A., Offin, M., Feldman, D., Hembrough, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.9777 · Cited by 556
Thuss-Patience, P. C., Shah, M. A., Ohtsu, A., Van Cutsem, E., Ajani, J. A., Castro, H., Mansoor, W., Chung, H. C., Bodoky, G., Shitara, K., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30111-0 · Cited by 547
Banerji, U., van Herpen, C. M. L., Saura, C., Thistlethwaite, F., Lord, S., Moreno, V., Macpherson, I. R., Boni, V., Rolfo, C., de Vries, E. G. E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30328-6 · Cited by 547
Tagawa, S. T., Balar, A. V., Petrylak, D. P., Kalebasty, A. R., Loriot, Y., Fléchon, A., Jain, R. K., Agarwal, N., Bupathi, M., Barthelemy, P., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03489 · Cited by 543
Doi, T., Shitara, K., Naito, Y., Shimomura, A., Fujiwara, Y., Yonemori, K., Shimizu, C., Shimoi, T., Kuboki, Y., Matsubara, N., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30604-6 · Cited by 505
Goldenberg, D. M., Cardillo, T. M., Govindan, S. V., Rossi, E. A., & Sharkey, R. M. (2015) · Oncotarget · doi:10.18632/oncotarget.4318 · Cited by 495
Tabernero, J., Hoff, P. M., Shen, L., Ohtsu, A., Shah, M. A., Cheng, K., Song, C., Wu, H., Eng-Wong, J., Kim, K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30481-9 · Cited by 490
Cancer Therapies Utilizing the Camptothecins: A Review of the in Vivo Literature
Venditto, V. J., & Simanek, E. E. (2010) · Molecular Pharmaceutics · doi:10.1021/mp900243b · Cited by 452
Scaltriti, M., Verma, C., Guzman, M., Jimenez, J., Parra, J. L., Pedersen, K., Smith, D. J., Landolfi, S., Ramon y Cajal, S., Arribas, J., et al. (2009) · Oncogene · doi:10.1038/onc.2008.432 · Cited by 439
Siena, S., Di Bartolomeo, M., Raghav, K., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Fakih, M., Elez, E., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00086-3 · Cited by 422
Coleman, R. L., Lorusso, D., Gennigens, C., González-Martín, A., Randall, L., Cibula, D., Lund, B., Woelber, L., Pignata, S., Forget, F., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00056-5 · Cited by 410
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
Schoenfeld, A. J., Arbour, K. C., Rizvi, H., Iqbal, A. N., Gadgeel, S. M., Girshman, J., Kris, M. G., Riely, G. J., Yu, H. A., & Hellmann, M. D. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz077 · Cited by 406
Bardia, A., Messersmith, W. A., Kio, E. A., Berlin, J. D., Vahdat, L., Masters, G. A., Moroose, R., Santin, A. D., Kalinsky, K., Picozzi, V., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.005 · Cited by 400
Self-citationPress, M. F., Slamon, D. J., Flom, K. J., Park, J., Zhou, J.-Y., & Bernstein, L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.094 · Cited by 391
Amiri-Kordestani, L., Blumenthal, G. M., Xu, Q. C., Zhang, L., Tang, S. W., Ha, L., Weinberg, W. C., Chi, B., Candau-Chacon, R., Hughes, P., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0012 · Cited by 351
Starodub, A. N., Ocean, A. J., Shah, M. A., Guarino, M. J., Picozzi, V. J., Vahdat, L. T., Thomas, S. S., Govindan, S. V., Maliakal, P. P., Wegener, W. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3321 · Cited by 340
Upregulation of Trop-2 quantitatively stimulates human cancer growth
Trerotola, M., Cantanelli, P., Guerra, E., Tripaldi, R., Aloisi, A. L., Bonasera, V, Lattanzio, R., Lange, R. D., Weidle, U. H., Piantelli, M., et al. (2013) · Oncogene · doi:10.1038/onc.2012.36 · Cited by 331
Bardia, A., Tolaney, S. M., Punie, K., Loirat, D., Oliveira, M., Kalinsky, K., Zelnak, A., Aftimos, P., Dalenc, F., Sardesai, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.002 · Cited by 326
Self-citationTwo Hundred Years of Cancer Research
DeVita, V. T., & Rosenberg, S. A. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1204479 · Cited by 318
Oshima, Y., Tanimoto, T., Yuji, K., & Tojo, A. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4526 · Cited by 313
Yamazaki, C. M., Yamaguchi, A., Anami, Y., Xiong, W., Otani, Y., Lee, J., Ueno, N. T., Zhang, N., An, Z., & Tsuchikama, K. (2021) · Nature Communications · doi:10.1038/s41467-021-23793-7 · Cited by 309
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
Li, B. T., Michelini, F., Misale, S., Cocco, E., Baldino, L., Cai, Y., Shifman, S., Tu, H.-Y., Myers, M. L., Xu, C., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0215 · Cited by 288
Sheng, X., Yan, X., Wang, L., Shi, Y., Yao, X., Luo, H., Shi, B., Liu, J., He, Z., Yu, G., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2488 · Cited by 284
Girish, S., Gupta, M., Wang, B., Lu, D., Krop, I. E., Vogel, C. L., Burris III, H. A., LoRusso, P. M., Yi, J.-H., Saad, O., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1817-3 · Cited by 262
Ocean, A. J., Starodub, A. N., Bardia, A., Vahdat, L. T., Isakoff, S. J., Guarino, M., Messersmith, W. A., Picozzi, V. J., Mayer, I. A., Wegener, W. A., et al. (2017) · Cancer · doi:10.1002/cncr.30789 · Cited by 244
Self-citationPeters, S., Stahel, R., Bubendorf, L., Bonomi, P., Villegas, A., Kowalski, D. M., Baik, C. S., Isla, D., Carpeno, J. D. C., Garrido, P., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1590 · Cited by 236
4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)
Senkus, E., Kaufman, B., Krop, I. E., Saghir, N. S. E., Penault-Llorca, F. M., Nakigudde, G., Cortés, J., Gelmon, K. A., Cardoso, F., Cardoso, M. J., et al. (2021) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/fjc4-5257 · Cited by 230
Self-citationTrop-2 Is a Determinant of Breast Cancer Survival
Ambrogi, F., Fornili, M., Boracchi, P., Trerotola, M., Relli, V., Simeone, P., La Sorda, R., Lattanzio, R., Querzoli, P., Pedriali, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096993 · Cited by 221
Human TROP-2 is a tumor-associated calcium signal transducer
Rapani, E., Sacchetti, A., Corda, D., & Alberti, S. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980529)76:5<671::aid-ijc10>3.0.co;2-7 · Cited by 220
Clinical Significance of TROP2 Expression in Colorectal Cancer
Ohmachi, T., Tanaka, F., Mimori, K., Inoue, H., Yanaga, K., & Mori, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1961 · Cited by 206
van der Lee, M. M. C., Groothuis, P. G., Ubink, R., van der Vleuten, M. A. J., van Achterberg, T. A., Loosveld, E. M., Damming, D., Jacobs, D. C. H., Rouwette, M., Egging, D. F., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0881-t · Cited by 201
Saleh, M. N., Sugarman, S., Murray, J., Ostroff, J. B., Healey, D., Jones, D., Daniel, C. R., LeBherz, D., Brewer, H., Onetto, N., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2282 · Cited by 196
FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma
Chang, E., Weinstock, C., Zhang, L., Charlab, R., Dorff, S. E., Gong, Y., Hsu, V., Li, F., Ricks, T. K., Song, P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2275 · Cited by 189
Sartore-Bianchi, A., Lonardi, S., Martino, C., Fenocchio, E., Tosi, F., Ghezzi, S., Leone, F., Bergamo, F., Zagonel, V., Ciardiello, F., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000911 · Cited by 185
TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity
Fong, D., Spizzo, G., Gostner, J. M., Gastl, G., Moser, P., Krammel, C., Gerhard, S., Rasse, M., & Laimer, K. (2008) · Modern Pathology · doi:10.1038/modpathol.3801001 · Cited by 173
Sharkey, R. M., McBride, W. J., Cardillo, T. M., Govindan, S. V., Wang, Y., Rossi, E. A., Chang, C.-H., & Goldenberg, D. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0670 · Cited by 172
(2021) · doi:10.1158/1078-0432.ccr-20-4175 · Cited by 172
Kumagai, K., Aida, T., Tsuchiya, Y., Kishino, Y., Kai, K., & Mori, K. (2020) · Cancer Science · doi:10.1111/cas.14686 · Cited by 171
Narayan, P., Osgood, C. L., Singh, H., Chiu, H.-J., Ricks, T. K., Chiu Yuen Chow, E., Qiu, J., Song, P., Yu, J., Namuswe, F., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4557 · Cited by 167
Wahby, S., Fashoyin‐Aje, L. A., Osgood, C. L., Cheng, J., Fiero, M. H., Zhang, L., Tang, S. W., Hamed, S. S., Song, P., Charlab, R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3119 · Cited by 165
Kalinsky, K. M., Diamond, J. R., Vahdat, L. T., Tolaney, S. M., Juric, D., O’Shaughnessy, J., Moroose, R. L., Mayer, I. A., Abramson, V. G., Goldenberg, D. M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.004 · Cited by 163
Self-citationJhaveri, K. L., Wang, X. V., Makker, V., Luoh, S.-W., Mitchell, E. P., Zwiebel, J. A., Sharon, E., Gray, R. J., Li, S., McShane, L. M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz291 · Cited by 151
TROP2 expression as prognostic marker for gastric carcinoma
Mühlmann, G., Spizzo, G., Gostner, J. M., Zitt, M., Maier, H. T., Moser, P. L., Gastl, G. A., Zitt, M., Müller, H. M., Margreiter, R., et al. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2008.060590 · Cited by 146
Lin, J. J., Chin, E., Yeap, B. Y., Ferris, L. A., Kamesan, V., Lennes, I. T., Sequist, L. V., Heist, R. S., Mino-Kenudson, M., Gainor, J. F., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.09.001 · Cited by 140
Mamounas, E. P., Untch, M., Mano, M. S., Huang, C., Geyer, C. E., von Minckwitz, G., Wolmark, N., Pivot, X. B., Küemmel, S., DiGiovanna, M. P., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.04.011 · Cited by 134
Smit, E. F., Nakagawa, K., Nagasaka, M., Felip, E., Goto, Y., Li, B. T., Pacheco, J. M., Murakami, H., Barlési, F., Saltos, A. N., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.9504 · Cited by 117
Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia
Baron, J. I., & Wang, E. S. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1478725 · Cited by 115
Wang, J., Liu, Y., Zhang, Q., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.1022 · Cited by 104
Saura, C., O’Shaughnessy, J., Aftimos, P. G., van den Tweel, E., Oesterholt, M., Escrivá-de-Romaní, S., Tueux, N. Q., Tan, T. Y., Lim, J. S. J., Ladoire, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.2088 · Cited by 101
Cortés, J., Kim, S.-B., Chung, W.-P., Im, S., Park, Y. H., Hegg, R., Kim, M., Tseng, L.-M., Petry, V., Chung, C.-F., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.2087 · Cited by 95
Self-citationElias, D. J., Hirschowitz, L., Kline, L. E., Kroener, J. F., Dillman, R. O., Walker, L. E., Robb, J. A., & Timms, R. M. (1990) · PubMed · Cited by 85
FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma
Richardson, N. C., Kasamon, Y. L., Chen, H., de Claro, R. A., Ye, J., Blumenthal, G. M., Farrell, A. T., & Pazdur, R. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0098 · Cited by 85
Histology-agnostic drug development — considering issues beyond the tissue
Pestana, R. C., Sen, S., Hobbs, B. P., & Hong, D. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0384-0 · Cited by 84
Bauzon, M., Drake, P. M., Barfield, R. M., Cornali, B. M., Rupniewski, I., & Rabuka, D. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1565859 · Cited by 81
The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer
Avellini, C., Licini, C., Lazzarini, R., Gesuita, R., Guerra, E., Tossetta, G., Castellucci, C., Giannubilo, S. R., Procopio, A. D., Alberti, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17407 · Cited by 79
Mitani, S., & Kawakami, H. (2020) · Cancers · doi:10.3390/cancers12020400 · Cited by 71
Perrone, E., Lopez, S., Zeybek, B., Bellone, S., Bonazzoli, E., Pelligra, S., Zammataro, L. A., Manzano, A., Manara, P., Bianchi, A., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00118 · Cited by 70
The paradox of precision medicine
Kimmelman, J., & Tannock, I. F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0016-0 · Cited by 67
Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S., Tamura, K., André, F., Iwata, H., Ito, Y., Tsurutani, J., et al. (2021) · Cancer Research · doi:10.1158/1538-7445.sabcs20-pd3-06 · Cited by 63
Self-citationSystematic Review: Targeting HER2 in Bladder Cancer
Koshkin, V. S., O’Donnell, P. H., Yu, E. Y., & Grivas, P. D. (2019) · Bladder Cancer · doi:10.3233/blc-180196 · Cited by 51
Hamblett, K. J., Hammond, P. W., Barnscher, S. D., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-3914 · Cited by 46
Spira, A. I., Lisberg, A. E., Sands, J. M., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.01.280 · Cited by 45
Yamaguchi, K., Bang, Y.-J., Iwasa, S., Sugimoto, N., Ryu, M.-H., Sakai, D., Chung, H. C., Kawakami, H., Yabusaki, H., Lee, J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.1928 · Cited by 43
Schettini, F., Barbao, P., Brasó‐Maristany, F., Galván, P., Martínez, D., Paré, L., Placido, S. D., Prat, A., & Guedan, S. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100102 · Cited by 42
Suzuki, M., Yagishita, S., Sugihara, K., Ogitani, Y., Nishikawa, T., Ohuchi, M., Teishikata, T., Jikoh, T., Yatabe, Y., Yonemori, K., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0397 · Cited by 42
Schneck, D. W., Butler, F., Dugan, W., et al. (1990) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1990.5 · Cited by 41
McGregor, B. A., & Sonpavde, G. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1667332 · Cited by 38
Jhaveri, K. L., Makker, V., Wang, V., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.100 · Cited by 29
Peng, Z., Liu, T., Wei, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.4560 · Cited by 29
Sayama, Y., Kaneko, M. K., & Kato, Y. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11731 · Cited by 28
Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box
Tarantino, P., Prat, A., Cortés, J., Cardoso, F., & Curigliano, G. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188487 · Cited by 27
Self-citationTargeting HER2 in breast cancer: new drugs and paradigms on the horizon
Tarantino, P., Morganti, S., & Curigliano, G. (2021) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2021.00037 · Cited by 26
Self-citationComputational selection of antibody-drug conjugate targets for breast cancer
Fauteux, F., Hill, J. J., Jaramillo, M., Pan, Y., Phan, S., Famili, F. A., & O'Connor‐McCourt, M. D. (2015) · Oncotarget · doi:10.18632/oncotarget.6679 · Cited by 23
Establishment of a novel anti-TROP2 monoclonal antibody TrMab-29 for immunohistochemical analysis
Sayama, Y., Kaneko, M. K., Takei, J., Hosono, H., Sano, M., Asano, T., & Kato, Y. (2021) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2020.100902 · Cited by 23
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
Li, B., Michelini, F., Misale, S., Cocco, E., Baldino, L., Cai, Y., Shifman, S. G., Tu, H.-Y., Myers, M., Xu, C., et al. (2020) · UCL Discovery (University College London) · Cited by 22
Tarantino, P., Mazzarella, L., Marra, A., Trapani, D., & Curigliano, G. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102169 · Cited by 19
Self-citationDumbrava, E. I., Sharma, M. R., Carvajal, R. D., Catenacci, D. V. T., Emens, L. A., Gadgeel, S. M., Hanna, G. J., Juric, D., Kang, Y., Lee, J., et al. (2021) · Cancer Research · doi:10.1158/1538-7445.sabcs20-ot-03-02 · Cited by 18
Bardia, A., Juric, D., Shimizu, T., Tolcher, A. W., Karim, R., Spira, A. I., Mukohara, T., Lisberg, A. E., Kogawa, T., Krop, I. E., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.213 · Cited by 18
Self-citationYamaguchi, K., Bang, Y., Iwasa, S., Sugimoto, N., Ryu, M., Sakai, D., Chung, H. C., Kawakami, H., Yabusaki, H., Lee, J., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.4048 · Cited by 16
Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting
Prete, S. D., Montella, L., Arpino, G., Buono, G., Buonerba, C., Dolce, P., Fiorentino, O., Aliberti, M., Febbraro, A., Savastano, C., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27603 · Cited by 12
Cited by
Multifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 521
Targeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 455
Optimizing the safety of antibody–drug conjugates for patients with solid tumours
Tarantino, P., Ricciuti, B., Pradhan, S. M., & Tolaney, S. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00783-w · Cited by 269
Self-citationThe Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
Colombo, R., Tarantino, P., Rich, J. R., LoRusso, P. M., & de Vries, E. G. E. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0708 · Cited by 254
Self-citationZhu, Y., Liu, K., Wang, K., & Zhu, H. (2023) · Cancer · doi:10.1002/cncr.34507 · Cited by 192
Metadata
- Authors
- Tarantino, P., Carmagnani Pestana, R., Corti, C., Modi, S., Bardia, A., Tolaney, S. M., Cortes, J., Soria, J., & Curigliano, G.
- Venue
- CA: A Cancer Journal for Clinicians
- Publisher
- Wiley
- Published
- 2021-11-12
- Volume
- 72
- Issue
- 2
- Pages
- 165-182
- ISSN
- 0007-9235 (ISSN-L)
- 1542-4863
- OpenAlex
- W3211745509
- Cited by
- 385
- References
- 114
- FWCI
- 30.00
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.